10-29-13 5:16 PM EDT | Email Article
   By Tess Stynes 

Gilead Sciences Inc.'s (GILD) third-quarter earnings rose 17% on strong sales growth led by biopharmaceutical company's newer HIV drugs--Stribild and Complera.

The company raised its 2013 net product sales outlook to $10.3 billion to $10.4 billion from its previous forecast for $10 billion to $10.2 billion.

Gilead is one of the world's largest makers of HIV drugs, but as sales growth in that area have slowed, the company has moved aggressively in recent years into hepatitis C and cancer, areas where Gilead has been making strides.

An advisory committee to the U.S. Food and Drug Administration last Friday unanimously recommended approval for Gilead's new hepatitis C drug--sofosbuvir- a decision that could come by mid-December. Gilead also recently said its experimental treatment for lymphocytic leukemia--known as idelalisib--worked so well in a late-stage trial that it was stopping the study early.

Gilead reported a profit of $788.6 million, or 47 cents a share, up from $675.5 million, or 43 cents a share, a year earlier. Excluding acquisition-related expenses and other items, adjusted earnings were up at 52 cents from 50 cents. Revenue increased 15% to $2.78 billion.

Analysts polled by Thomson Reuters recently expected per-share profit of 48 cents and revenue of $2.72 billion.

Sales growth was led by strong demand for Gilead's newer HIV drugs Stribild--introduced in the U.S. in August 2012 and Complera--which received U.S. approval in August 2011.

Complera sales more than doubled to $210.7 million from a year earlier, while Stribild sales surged to $144 million from $17.5 million.

Shares were up 25 cents at $69.75 in recent after-hours trading Tuesday. Through the close, the stock is up 89% this year.


Write to Tess Stynes at tess.stynes@wsj.com


Order free Annual Report for Gilead Sciences, Inc.

Visit http://djnweurope.ar.wilink.com/?ticker=US3755581036 or call +44 (0)208 391 6028

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

October 29, 2013 17:16 ET (21:16 GMT)

Copyright (c) 2013 Dow Jones & Company, Inc.
Add a Comment

News   More...

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar

Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Content Partners
Morningstar - 2013/10/29 - Gilead 3rd-Quarter Profit Up 17% as New HIV Drugs Lead Sales Growth
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Author |  Collection |  Interest |  Popularity

Previous: Gildan Activewear Will Hold its Fiscal 2013 Fourth Quarter and Full Year Results Conference Call at 8:30 AM ET on November 21, 2013  |  Next: Gilead Announces Executive Promotions